These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 16455630

  • 21. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW.
    Cancer; 1996 Nov 01; 78(9):1861-70. PubMed ID: 8909304
    [Abstract] [Full Text] [Related]

  • 24. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L.
    J Nucl Med; 1995 Apr 01; 36(4):586-92. PubMed ID: 7699446
    [Abstract] [Full Text] [Related]

  • 25. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.
    Bardiès M, Bardet S, Faivre-Chauvet A, Peltier P, Douillard JY, Mahé M, Fiche M, Lisbona A, Giacalone F, Meyer P, Gautherot E, Rouvier E, Barbet J, Chatal JF.
    J Nucl Med; 1996 Nov 01; 37(11):1853-9. PubMed ID: 8917192
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.
    J Nucl Med; 2009 Mar 01; 50(3):444-53. PubMed ID: 19223402
    [Abstract] [Full Text] [Related]

  • 28. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH.
    J Nucl Med; 2003 Mar 01; 44(3):400-11. PubMed ID: 12621007
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD.
    J Nucl Med; 2003 Jan 01; 44(1):67-76. PubMed ID: 12515878
    [Abstract] [Full Text] [Related]

  • 31. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 32. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [Abstract] [Full Text] [Related]

  • 33. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF, Loussouarn A, Bardiès M, Gautherot E, Gruaz-Guyon A, Saï-Maurel C, Barbet J, Curtet C, Chatal JF, Faivre-Chauvet A.
    J Nucl Med; 2001 Jan 01; 42(1):146-53. PubMed ID: 11197965
    [Abstract] [Full Text] [Related]

  • 34. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.
    J Nucl Med; 2010 Apr 01; 51(4):624-31. PubMed ID: 20351352
    [Abstract] [Full Text] [Related]

  • 35. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
    Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.
    Clin Cancer Res; 2009 Jul 01; 15(13):4484-92. PubMed ID: 19549771
    [Abstract] [Full Text] [Related]

  • 36. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, Olivier P, Leccia F, Corcuff B, Huglo D, Proye C, Rouvier E, Meyer P, Chatal JF.
    J Nucl Med; 1998 Jul 01; 39(7):1172-8. PubMed ID: 9669389
    [Abstract] [Full Text] [Related]

  • 37. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC, Bigner DD.
    Clin Cancer Res; 1996 Jun 01; 2(6):963-72. PubMed ID: 9816257
    [Abstract] [Full Text] [Related]

  • 38. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec 01; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 39. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.
    Clin Cancer Res; 2005 Jul 01; 11(13):4818-26. PubMed ID: 16000579
    [Abstract] [Full Text] [Related]

  • 40. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
    Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.
    Clin Cancer Res; 2000 Feb 01; 6(2):406-14. PubMed ID: 10690517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.